Form 4: Arcutis Biotherapeutics Director Sue-Jean Lin Reports Stock and Option Transactions

Director Sue-Jean Lin reports acquisition of restricted stock units and stock options in Arcutis Biotherapeutics.

Summary

• Sue-Jean Lin, a director of Arcutis Biotherapeutics, reported transactions involving the company's securities on June 14, 2024.
• Lin acquired 10,139 Restricted Stock Units (RSUs) and 27,052 stock options.
• The RSUs vest in full on the one-year anniversary of the grant date, contingent upon continuous service as a non-employee director.
• The stock options also vest and become exercisable as to 100% on the first anniversary of June 14, 2024, subject to continuous service.
• Lin also disposed of 10,139 common stock shares.
• Following these transactions, Lin beneficially owns 19,126 shares of common stock and 27,052 stock options.

Sentiment

Score: 7

Explanation: The document reflects standard insider transactions, which are generally neutral to positive as they align management and shareholder interests. The grants of RSUs and options are a positive sign of incentivization.

Positives

• The grant of RSUs and stock options to a director aligns their interests with those of the shareholders.
• The vesting schedules incentivize continued service and commitment to the company.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, such as directors and officers, ensuring fair market practices.

Stakeholder Impact

• Shareholders may view the granting of RSUs and stock options to directors as a positive sign, aligning their interests with the company's long-term success.
• Employees may see this as a sign of stability and commitment from the board.

Key Dates